Diagnosing hepatitis C in clinical practice: A literature review;Diagnóstico da hepatite C na prática médica: Revisão da literatura

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 9, Issue 3, 2001, Pages 161-168

  De Mello Brandao A B ^a   Fuchs, S C ^a   Dos Anjos Silva, M A ^a   Emer, L F ^a  

^a NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIBODY SPECIFICITY; ARTICLE; CLINICAL PRACTICE; COST MINIMIZATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD;

EID: 0035032993     PISSN: 10204989     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1020-49892001000300005     Document Type: Article

References (70)

1. Hepatitis C: Global prevalence. Update
2. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
3. Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis
4. Diagnostic tests for hepatitis C
5. Hepatitis C virus: Background and strategies for cloning a major etiologic agent of PT-NANB
6. Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory
7. Use and interpretation of HCV diagnostic tests in the clinical setting
8. Antibodies to hepatitis C virus in low-risk blood donors: Implications for counseling positive donors
9. Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors
10. Infectivity of blood seropositive for hepatitis C virus antibodies
11. New kit on the block: Evaluation of a second-generation assays for detection of antibody to the hepatitis C virus
12. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays
13. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay
14. Evaluation of an enzyme immunoassay for hepatitis C virus antibody detection using a recombinant protein derived from the core region of hepatitis C virus genome
15. Improved detection of anti-VHC in post-transfusion hepatitis by a third-generation ELISA
16. Third-generation hepatitis C virus tests in asymptomatic anti-HCV-positive blood donors
17. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay
18. Evaluation of third-generation screening and confirmatory assays for HCV antibodies
19. Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay
20. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients
21. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion
22. Failure of 2nd- and 3rd-generation HCV ELISA and RIBA to detect HCV polymerase chain reaction-positive donations
23. Persistence of HCV-RNA in a blood donor with negative antibody assays
24. Detection of antibodies to hepatitis C virus in seronegative patients using an immune complex dissociation assay
25. Evaluation of laboratory assays for screening antibody to hepatitis C virus
26. HCV ELISA donor screening tests performance from seven different kits [resumo]
27. Diagnosis of hepatitis C
28. Hepatitis C: Diagnostic assays
29. Automated RIBA hepatitis C virus (HCV) strip immunoblot assay for reproducible HCV diagnosis
30. New perspectives in the diagnosis of hepatitis C
31. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
32. EASL international consensus conference on hepatitis C. Paris, 26-28 February 1999. Consensus statement
33. Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients
34. Viral hepatitis A through G
35. Evaluation of RIBA™ HCV2.0 SIA indeterminate specimens by RIBA™ HCV 30 SIA and HCV-RNA by PCR
36. Reliability of third-generation recombinant immunoblot assay for hepatitis C virus
37. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay
38. Third-generation recombinant immunoblot assay: Comparison of reactivities according to hepatitis C virus genotype
39. A comparative evaluation of the sensitivity of five antihepatitis C virus immunoblot assays
40. Hepatitis C
41. Detection of hepatitis C virus RNA: Comparison of one-stage polymerase chain reaction (PCR) with nested-set PCR
42. Avoiding false positives with PCR
43. Reliability of polymerase chain reaction for detection of hepatitis C virus
44. Comparative study of conventional and novel strategies for the detection of hepatitis C virus RNA in serum: Amplicor, branched-DNA, NASBA and in-house PCR
45. Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: Comparison with nested amplification and antibody testing
46. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting
47. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA
48. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA
49. Hepatitis C virus infection in dialysis units: Prevalence of HCV RNA and antibodies to HCV
50. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients
51. Clinical manifestations of hepatitis C
52. Hepatitis C: The clinical spectrum of disease
53. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
54. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications
55. Measuring hepatitis C viremia in clinical samples: Can we trust the assays?
56. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NABSA, and Monitor assays
57. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment
58. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
59. α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C
60. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C
61. Real-time detection system for quantification of hepatitis C virus genome
62. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
63. Variability of hepatitis C virus
64. The "gold standard", accuracy, and the current concepts: Hepatitis C virus genotype and viremia
65. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
66. Sequence variability in the 5′ non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity
67. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
68. Molecular tools for the treatment of hepatitis C
69. Two distinct subtypes of hepatitis C virus defined by antibodies direct to the putative core protein